Eli Lilly sticks to premium pricing for its innovator drug ahead of generics wave
Published on: March 2, 2026, 12:09 a.m. | Source: The Economic Times
Eli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite its premium pricing, even as lower-cost semaglutide generics prepare to enter the Indian market.Winselow Tucker, president and general manager of Eli Lilly and Company (India), told ET that the company sees room for both branded innovator drugs and generics to thrive simultaneously in the rapidly expanding domestic segment.
